Marshall Wace
KYTX icon

Marshall Wace’s Kyverna Therapeutics KYTX Stock Holding History

Marshall Wace’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.23M Buy
605,512
+469,912
+347% +$3.92M 0.01% 1281
2025
Q4 		$1.27M Buy
+135,600
New +$1.01M ﹤0.01% 1810
2025
Q3 		– Sell
-62,057
Closed -$191K – 3500
2025
Q2 		$191K Buy
62,057
+37,496
+153% +$92.7K ﹤0.01% 2465
2025
Q1 		$47.4K Buy
24,561
+9,320
+61% +$27.5K ﹤0.01% 2537
2024
Q4 		$57K Sell
15,241
-16,982
-53% -$81.4K ﹤0.01% 2483
2024
Q3 		$158K Buy
32,223
+21,823
+210% +$168K ﹤0.01% 2324
2024
Q2 		$78K Sell
10,400
-145,355
-93% -$2.22M ﹤0.01% 2412
2024
Q1 		$3.87M Buy
+155,755
New +$4.35M 0.01% 1102

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Marshall Wace's KYTX Position: Q1 2026 in Review

Marshall Wace increased its Kyverna Therapeutics (KYTX) stake by 347% in Q1 2026, buying an estimated $3.92M and bringing the position to 605,512 shares worth $5.23M. The position accounts for 0.01% of the portfolio, ranked #1281.

Marshall Wace first reported a position in KYTX in Q1 2024 and has held it in 8 quarters since. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • Marshall Wace held 605,512 shares of Kyverna Therapeutics worth $5.23M as of Q1 2026.
  • Marshall Wace bought 469,912 Kyverna Therapeutics shares in Q1 2026, an estimated $3.92M.
  • Kyverna Therapeutics made up 0.01% of Marshall Wace's portfolio in Q1 2026, its #1281 holding.
  • Marshall Wace first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 8 quarters since.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.